Experience

Davis Polk advised the joint lead managers on a Rule 144A/Regulation S offering by SP Group Treasury Pte. Ltd. of $600 million aggregate principal amount of 3.375% notes due 2029 under its…

Davis Polk advised CStone Pharmaceuticals in connection with its initial public offering and listing on the Hong Kong Stock Exchange and an international offering in reliance on Rule 144A…

Davis Polk advised the initial purchasers in connection with the Regulation S offering of $250 million 7.50% senior notes due 2021 by ENN Clean Energy International Investment Limited,…

Davis Polk is advising Roche on its approximately $4.3 billion acquisition of Spark Therapeutics, Inc. The transaction, which is expected to be completed in the second quarter of 2019, has…

Davis Polk advised the sales agents in connection with the establishment of an SEC-registered at-the-market offering program by MDU Resources Group, Inc. of up to 10,000,000 shares of…

Davis Polk advised the underwriters in connection with an SEC-registered offering by Weyerhaeuser Company of $750 million aggregate principal amount of its 4.00% senior notes due 2029…

Davis Polk advised the joint book-running managers in connection with a $4.5 billion registered offering by Eli Lilly and Company of $1.15 billion aggregate principal amount of its 3.375%…

Davis Polk is advising Pernix Therapeutics Holdings, Inc. in connection with its restructuring under chapter 11 of the United States Bankruptcy Code, entry into a “stalking horse” asset…

Davis Polk advised the joint book-running managers in connection with a $20 million SEC-registered common stock offering by Sienna Biopharmaceuticals, Inc. The common stock is listed on the…

Davis Polk advised the representative of the initial purchasers in connection with a Rule 144A/Regulation S offering of $1 billion aggregate principal amount of 6.750% senior notes due 2024…